An Observational Cohort Study to Obese Patients With Weight Cycling

Plain-language summary

This observational study aims to examine obese individuals who experience repeated cycles of losing and regaining weight (weight cycling). It enrolls people aged 18-50 who are of normal weight or obese and are able to follow a weight-loss plan. This is an observational study without a phase and is active but not currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Peking Union Medical College Hospital

Start date

4/8/2022

Estimated completion

12/20/2028

Countries

China

Related genes

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Normal weight (18.5 ≤ BMI \< 24 kg/m2) or obese (28 ≤ BMI \< 35 kg/m2);
* Aged 18 to 50 years old;
* Han nationality;
* Able to follow the weight-loss prescription;
* Able to sign consent independently;
* Definition of Weight cycling: Loss weight more than once in the past 3 years, and weight regain exceeds 5% or more of the baseline weight of losing weight.

Exclusion Criteria:

* Bodyweight has changed more than ±10% in the past year;
* Taking drugs known to affect body weight (orlistat, GLP-1 receptor agonists, etc.);
* Taking drugs known to affect glucolipid metabolism (such as sulfonylureas, biguanides, acarbose, or insulin) have been taken in the past 6 months or at present; Lipid-lowering drugs such as statins, bate, niacin, and ezetimibe; Diuretics, β -blockers and other antihypertensive drugs; Glucocorticoid, thyroid hormone, etc.);
* Women who are currently pregnant or nearly 3 months breastfeeding;
* With serious eating disorders or vigorous exercise to lose weight;
* Hard physical workers;
* History of serious cardiovascular disease;
* Acute, chronic, or active gastrointestinal diseases;
* Serious systemic diseases;
* History of serious mental disorders;
* Cancer or active tumor;
* Secondary obesity or drug obesity patients: including hypothalamic obesity, pituitary obesity, hypercortisolism, and hypogonadism obesity;
* Severe liver dysfunction (ALT, AST, ALP, and TBil \> the upper limit of 2.5 times reference value);
* Chronic kidney disease (eGFR \< 60 mL/min/1.73 m2 or eGFR \< 90 mL/min/1.73 m2 with proteinuria);
* Those who are considered by the researcher to be poor compliance or unable to complete this research well.